Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas

Peter A. Riedell, Wei Ting Hwang, Loretta J. Nastoupil, Martina Pennisi, Joseph P. McGuirk, Richard T. Maziarz, Veronika Bachanova, Olalekan O. Oluwole, Jamie Brower, Oscar A. Flores, Nausheen Ahmed, Levanto Schachter, Kharmen Bharucha, Bhagirathbhai R. Dholaria, Stephen J. Schuster, Miguel Angel Perales, Michael R. Bishop, David L. Porter

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-directed chimeric antigen receptor (CAR) T cell therapies approved for the treatment of relapsed/refractory aggressive B cell lymphomas. We present a multicenter retrospective study among centers that prescribe either commercial product to evaluate usage patterns, safety and efficacy outcomes, and resource utilization. Data collection included all patients from 8 US centers who underwent apheresis between May 1, 2018, and July 31, 2019. Patient selection, toxicity management, and disease assessment followed institutional practices. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were graded according to American Society for Transplantation and Cellular Therapy consensus criteria, and tumor responses were assessed according to the Lugano 2014 classification scheme. A total of 260 patients underwent apheresis, including 168 (65%) for axi-cel and 92 (35%) for tisa-cel. Among the infused patients, the median age was 59 years for axi-cel recipients and 67 years for tisa-cel recipients (P < .001). The median time from apheresis to infusion was 28 days for axi-cel recipients and 45 days for tisa-cel recipients (P < .001). Sixty-one percent of the axi-cel recipients and 43% of the tisa-cel recipients would have been ineligible for the ZUMA-1 and JULIET trials, respectively. Grade ≥3 CRS occurred in 9% of axi-cel recipients and in 1% of tisa-cel recipients (P = .017), and grade ≥3 ICANS was seen in 38% of axi-cel recipients and 1% of tisa-cel recipients (P < .001). Inpatient cell therapy infusion was common (92% in axi-cel recipients, 37% in tisa-cel recipients). The day 90 overall response rate was 52% in the axi-cel group and 41% in the tisa-cel group (P =. 113), with complete response in 44% and 35%, respectively (P =. 319). Twelve-month progression-free survival (42% versus 32%; P =. 206) and overall survival (62% versus 59%; P =. 909) rates were comparable in the axi-cel and tisa-cel groups. Baseline characteristics differed between the 2 groups, although response rates and survival outcomes were comparable, albeit lower than those in the pivotal trials. Safety and resource utilization appear to be key differentiators between axi-cel and tisa-cel.

Original languageEnglish (US)
Pages (from-to)669-676
Number of pages8
JournalTransplantation and Cellular Therapy
Issue number10
StatePublished - Oct 2022


  • Aggressive large B cell lymphoma
  • CAR T cell therapy outcomes
  • CAR T cell toxicity
  • Chimeric antigen receptor T cell therapy
  • Resource utilization

ASJC Scopus subject areas

  • Immunology and Allergy
  • Molecular Medicine
  • Hematology
  • Cell Biology
  • Transplantation


Dive into the research topics of 'Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas'. Together they form a unique fingerprint.

Cite this